R&D The value of unstructured data for drug companies Advancements in medical AI now allow pharmaceutical companies to leverage unstructured clinical data at scale.
R&D Navigating the unique challenges of epilepsy in women's heal... Epilepsy affects women differently than men, owing to the complexity of brain health and the historical lack of investment in women’s health.
R&D The glimmer of opportunity behind the storm: Ali Pashazadeh ... Former surgeon and investment banker Ali Pashazadeh, CEO of Treehill, discusses the current ‘perfect storm’ in biotech.
R&D The impact of generative AI on protein design for drug disco... Artificial Intelligence (AI) is at the heart of the latest global transformation, not least within the biopharmaceutical industry.
R&D Changing the drug development treatment paradigm: Hilary Eat... Hilary Eaton, a rare disease advocate and chief business officer at Profluent, discusses AI-first protein design and accelerating biomedicine.
R&D How Europe can harness the full potential of biosimilars Biosimilars - clinically equivalent alternatives to original biologic drugs - play a vital role in addressing unmet health needs.
News Major trial launched to explore GLP-1 benefit in dementia A $100m trial has been launched to see if lifestyle changes coupled with GLP-1 agonists or similar incretins can reduce the risk of dementia.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
